| 2021 | ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K | PU |
| 2021 | ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis.. | AQ |
| 2021 | Merck Completes Tender Offer to Acquire Acceleron Pharma Inc. | AQ |
| 2021 | Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer | BU |
| 2021 | Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Ten.. | BU |
| 2021 | Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K | PU |
| 2021 | ACCELERON : Q3 Earnings Snapshot | AQ |
| 2021 | ACCELERON PHARMA INC Management's Discussion and Analysis of Financial Condition and
R.. | AQ |
| 2021 | Acceleron Reports Third Quarter 2021 Financial Results | BU |
| 2021 | Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o.. | AQ |
| 2021 | Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders | BU |
| 2021 | ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales | BU |
| 2021 | ACCELERON INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequacy of Pri.. | BU |
| 2021 | ACCELERON PHARMA : Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merc.. | BU |
| 2021 | ACCELERON PHARMA : Merck spends $11.5B for Acceleron, possible blockbuster drug | AQ |
| 2021 | ACCELERON PHARMA : REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation .. | PU |
| 2021 | ACCELERON PHARMA INC : Entry into a Material Definitive Agreement, Other Events, Financial.. | AQ |
| 2021 | Kraton, Hess rise; Apple, Moderna fall | AQ |
| 2021 | ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results.. | AQ |
| 2021 | ACCELERON : Q2 Earnings Snapshot | AQ |
| 2021 | ACCELERON PHARMA : Reports Second Quarter 2021 Financial Results | BU |
| 2021 | ACCELERON PHARMA : Results of Operations and Financial Condition (Form 8-K) | PU |
| 2021 | ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : Announces Second Quarter 2021 REBLOZYL® Net Sales | BU |
| 2021 | ACCELERON PHARMA : to Webcast Second Quarter 2021 Financial Results on August 5, 2021 | BU |
| 2021 | ACCELERON PHARMA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8.. | AQ |
| 2021 | ACCELERON PHARMA : Research & Development Day 2021 | PU |
| 2021 | ACCELERON PHARMA INC : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : Reblozyl was generally well tolerated and improvements in hemoglobin co.. | PU |
| 2021 | ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : to Host Virtual Research and Development (R&D) Day on June 22, 2021 | BU |
| 2021 | ACCELERON PHARMA : ATS 2021 International Conference | PU |
| 2021 | ACCELERON PHARMA : Data presented show maintained or improved responses in multiple effica.. | PU |
| 2021 | ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : For The First Time, FDA Cites Sponsor For Failure To Submit Clinical Tr.. | AQ |
| 2021 | ACCELERON PHARMA : Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept.. | BU |
| 2021 | ACCELERON PHARMA : Presents Interim Results from the Open-label Extension of the PULSAR Ph.. | BU |
| 2021 | ACCELERON PHARMA : Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 Eu.. | BU |
| 2021 | ACCELERON PHARMA : to Host Conference Call and Webcast to Review Clinical Trial Updates, P.. | BU |
| 2021 | CLINICAL TRIALS : Does FDA's Notice To Acceleron Signal A New Era Of Enforcement For Resul.. | AQ |
| 2021 | ACCELERON PHARMA : Q1 Earnings Call | PU |
| 2021 | ACCELERON PHARMA : REBLOZYL, the first and only erythroid maturation agent, was approved b.. | PU |
| 2021 | ACCELERON : Q1 Earnings Snapshot | AQ |
| 2021 | ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results.. | AQ |
| 2021 | ACCELERON PHARMA : Reports First Quarter 2021 Financial Results | BU |
| 2021 | ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : Results of Operations and Financial Condition | PU |
| 2021 | ACCELERON PHARMA : Announces First Quarter 2021 REBLOZYL® Net Sales | BU |
| 2021 | ACCELERON PHARMA : receives FDA Notice of Noncompliance | AQ |
| 2021 | ACCELERON PHARMA : to Webcast First Quarter 2021 Financial Results on May 6, 2021 | BU |
| 2021 | ACCELERON PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : Announces Clinical Trial Updates, Preclinical Presentations on Sotaterc.. | BU |
| 2021 | ACCELERON PHARMA : New England Journal of Medicine Publishes Results of the PULSAR Phase 2.. | BU |
| 2021 | ACCELERON : 4Q Earnings Snapshot | AQ |
| 2021 | ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results.. | AQ |
| 2021 | ACCELERON PHARMA : Reports Fourth Quarter and Full Year 2020 Financial Results | BU |
| 2021 | ACCELERON PHARMA : to Participate in Two Upcoming Healthcare Investor Conferences | BU |
| 2021 | ACCELERON PHARMA : to Webcast Fourth Quarter and Full Year 2020 Financial Results on Febru.. | BU |
| 2021 | ACCELERON PHARMA : Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment.. | BU |
| 2021 | ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | ACCELERON PHARMA : Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales | BU |
| 2021 | IMARA : Announces the Appointment of Kenneth Attie M.D. as Chief Medical Officer | AQ |
| 2021 | ACCELERON PHARMA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8.. | AQ |
| 2021 | ACCELERON PHARMA : to Participate in the 39th Annual J.P. Morgan Healthcare Conference on .. | BU |
| 2020 | ACCELERON PHARMA : Receives Orphan Designation from the European Commission (EC) for Sotat.. | BU |
| 2020 | ACCELERON PHARMA : Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of .. | BU |
| 2020 | ACCELERON PHARMA : Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research o.. | AQ |
| 2020 | ACCELERON PHARMA : Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sot.. | AQ |
| 2020 | ACCELERON PHARMA INC : Regulation FD Disclosure, Other Events, Financial Statements and Ex.. | AQ |
| 2020 | ACCELERON PHARMA : Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sot.. | BU |
| 2020 | ACCELERON PHARMA : Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research o.. | BU |
| 2020 | ACCELERON PHARMA : Announces Clinical Trial Updates, Preclinical Presentation on Sotaterce.. | BU |
| 2020 | ACCELERON : 3Q Earnings Snapshot | AQ |
| 2020 | ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results.. | AQ |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
